Marc A. Bollet
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Marc A. Bollet has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
Alain Fourquet
Department of Radiation Oncology, Institut Curie, Paris cedex 05, Paris 75248, France; Department of Radiation Oncology, Institut Curie, Paris cedex 05, Paris 75248, France
9 shared publicationsBrigitte Sigal-Zafrani
Département d ' oncologie radiothérapie (MAB, AF), Service de Bio-informatique (NS, PN GR PH EB
6 shared publicationsAlexia Savignoni
Department of Biostatistics, Institut Curie, Paris, France
5 shared publicationsFrançois Campana
Department of Radiation Oncology, Institut Curie, Paris, France
5 shared publications- Alain Fourquet
Department of radiation oncology, institut Curie, 75005 Paris, France
4 shared publications F Campana
4 shared publications
Latest Publications
- 1 August 2010
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 10 (8) , 1215-1227
Prognostic factors for local recurrence following breast-conserving treatment in young women
(2010). Prognostic factors for local recurrence following breast-conserving treatment in young women. Expert Review of Anticancer Therapy: Vol. 10, No. 8, pp. 1215-1227.
- 1 August 2010
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 10 (8) , 1215-1227
Prognostic factors for local recurrence following breast-conserving treatment in young women
(2010). Prognostic factors for local recurrence following breast-conserving treatment in young women. Expert Review of Anticancer Therapy: Vol. 10, No. 8, pp. 1215-1227.
- Open Access
- 22 July 2010
- Published by Springer Nature in Genome Biology
- Vol. 11 (7) , R76
Analysis of the copy number profiles of several tumor samples from the same patient reveals the successive steps in tumorigenesis
We present a computational method, TuMult, for reconstructing the sequence of copy number changes driving carcinogenesis, based on the analysis of several tumor samples from the same patient. We demonstrate the reliability of the method with simulated data, and describe applications to three different cancers, showing that TuMult is a valuable tool for the establishment of clonal relationships between tumor samples and the identification of chromosome aberrations occurring at crucial steps in cancer progression.
- 22 July 2010
- Published by Springer Nature in Genome Biology
- Vol. 11 (7) , R76
Open AccessAnalysis of the copy number profiles of several tumor samples from the same patient reveals the successive steps in tumorigenesis
We present a computational method, TuMult, for reconstructing the sequence of copy number changes driving carcinogenesis, based on the analysis of several tumor samples from the same patient. We demonstrate the reliability of the method with simulated data, and describe applications to three different cancers, showing that TuMult is a valuable tool for the establishment of clonal relationships between tumor samples and the identification of chromosome aberrations occurring at crucial steps in cancer progression.
- 20 May 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (15) , 651
Long-term results of a phase II trial of preoperative concurrent radiochemotherapy for breast cancers.
651 Background: Concurrent radiotherapy (RT) and chemotherapy (CT), two effective treatments for breast cancers (BC), has seldom been reported in the preoperative setting. This phase II trial was designed to investigate its efficacy for operable, nonmetastatic BC not amenable to initial breast-conserving surgery (BCS). The primary endpoint, the in-breast pathological complete response, was 27% with acceptable acute toxicity (Bollet et al., Eur J Cancer, 2006). Methods: From 2001 to 2003, 60 women were included (planned sample size = 50), 1 withdrew her consent leaving 59 studied patients (pts). CT consisted of 4 cycles of 5-FU, 500 mg/m2/d, continuous infusion (d1–d5) and vinorelbine, 25 mg/m2 (d1; d6). Starting with the second cycle, RT delivered 50 Gy to the breast and 46 Gy to the internal mammary and supra/infra-clavicular areas. Breast surgery and axillary lymph node dissection were then performed. Adjuvant treatment consisted of a 16 Gy boost to the tumour bed after BCS; FEC (4 cycles of fluorouracil 500 mg/m2, cyclophosphamide 500 mg/m2, and epirubicin 100 mg/m2, d1;d21) in the case of axillary involvement and hormone-therapy in the case of positive hormone receptors. Median follow-up was 83 months (64-96). Late toxicity was scored according to CTCAE-V3. Results: BCS was performed in 41 (69%) pts, mastectomy in the remaining 18 (31%). Seven pts died of their cancer, 2 developed second non-breast cancers, 3 contralateral BC, 2 local and 7 regional recurrences and 13 distant metastases. Overall and distant- disease-free survivals at 5 years were respectively 88% (95%CI 80-98) and 83% (95%CI 74-93) whereas locoregional and local controls were 90% (95%CI 82-98) and 97% (95%CI 92-100). Late toxicity was assessable at last diagnosis in 51 pts (86%). Four (7%) experienced grade 3 toxicities (1 telangectasia, 3 fibroses), 16 (27%) developed grade 2 (11 fibroses, 10 telangectasia, 1 lymphoedema, 1 dyspnea). Cosmetic results, assessed in 35 of the 41 pts (85%) who retained their breasts, were poor in 4 pts (10%). Conclusions: Preoperative concurrent administration of RT and CT is an effective regimen. Long-term toxicity is moderate. This association should undergo further evaluations in prospective trials. No significant financial relationships to disclose.
- 20 May 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (15) , 651
Long-term results of a phase II trial of preoperative concurrent radiochemotherapy for breast cancers.
651 Background: Concurrent radiotherapy (RT) and chemotherapy (CT), two effective treatments for breast cancers (BC), has seldom been reported in the preoperative setting. This phase II trial was designed to investigate its efficacy for operable, nonmetastatic BC not amenable to initial breast-conserving surgery (BCS). The primary endpoint, the in-breast pathological complete response, was 27% with acceptable acute toxicity (Bollet et al., Eur J Cancer, 2006). Methods: From 2001 to 2003, 60 women were included (planned sample size = 50), 1 withdrew her consent leaving 59 studied patients (pts). CT consisted of 4 cycles of 5-FU, 500 mg/m2/d, continuous infusion (d1–d5) and vinorelbine, 25 mg/m2 (d1; d6). Starting with the second cycle, RT delivered 50 Gy to the breast and 46 Gy to the internal mammary and supra/infra-clavicular areas. Breast surgery and axillary lymph node dissection were then performed. Adjuvant treatment consisted of a 16 Gy boost to the tumour bed after BCS; FEC (4 cycles of fluorouracil 500 mg/m2, cyclophosphamide 500 mg/m2, and epirubicin 100 mg/m2, d1;d21) in the case of axillary involvement and hormone-therapy in the case of positive hormone receptors. Median follow-up was 83 months (64-96). Late toxicity was scored according to CTCAE-V3. Results: BCS was performed in 41 (69%) pts, mastectomy in the remaining 18 (31%). Seven pts died of their cancer, 2 developed second non-breast cancers, 3 contralateral BC, 2 local and 7 regional recurrences and 13 distant metastases. Overall and distant- disease-free survivals at 5 years were respectively 88% (95%CI 80-98) and 83% (95%CI 74-93) whereas locoregional and local controls were 90% (95%CI 82-98) and 97% (95%CI 92-100). Late toxicity was assessable at last diagnosis in 51 pts (86%). Four (7%) experienced grade 3 toxicities (1 telangectasia, 3 fibroses), 16 (27%) developed grade 2 (11 fibroses, 10 telangectasia, 1 lymphoedema, 1 dyspnea). Cosmetic results, assessed in 35 of the 41 pts (85%) who retained their breasts, were poor in 4 pts (10%). Conclusions: Preoperative concurrent administration of RT and CT is an effective regimen. Long-term toxicity is moderate. This association should undergo further evaluations in prospective trials. No significant financial relationships to disclose.
- 17 May 2010
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 79 (4) , 1055-1063
Management of Inflammatory Breast Cancer After Neoadjuvant Chemotherapy
- 17 May 2010
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 79 (4) , 1055-1063
Management of Inflammatory Breast Cancer After Neoadjuvant Chemotherapy
- Open Access
- 28 July 2009
- Published by Springer Nature in Breast Cancer Research
- Vol. 11 (4) , R54
Tumor aromatase expression as a prognostic factor for local control in young breast cancer patients after breast-conserving treatment
Introduction: We sought to determine whether the levels of expression of 17 candidate genes were associated with locoregional control after breast-conserving treatments of early-stage breast cancers in young, premenopausal women. Methods: Gene expression was measured by using RT-PCR in the breast tumors of a series of 53 young (younger than 40 years), premenopausal patients. All treatments consisted of primary breast-conserving surgery followed by whole-breast radiotherapy (± regional lymph nodes) with or without systemic treatments (chemotherapy ± hormone therapy). The median follow-up was 10 years. Results: The 10-year locoregional control rate was 70% (95% CI, 57% to 87%). In univariate analysis, no clinical/pathologic prognostic factors were found to be significantly associated with decreased locoregional control. Expression of three genes was found to be significantly associated with an increased locoregional recurrence rate: low estrogen-receptor β, low aromatase, and high GATA3. Two others were associated with only a trend (P < 0.10): low HER1 and SKP2. In multivariate analysis, only the absence of aromatase was significantly associated with an increased locoregional recurrence rate (P = 0.003; relative risk = 0.49; 95% CI 0.29 to 0.82). Conclusions: Recent data give credit to the fact that breast cancer in young women is a distinct biologic entity driven by special oncogenic pathways. Our results highlight the role of estrogen-signaling pathways (mainly CYP19/aromatase, GATA3, and ER-β) in the risk of locoregional recurrence of breast cancer in young women. Confirmation in larger prospective studies is needed.
- 28 July 2009
- Published by Springer Nature in Breast Cancer Research
- Vol. 11 (4) , R54
Open AccessTumor aromatase expression as a prognostic factor for local control in young breast cancer patients after breast-conserving treatment
Introduction: We sought to determine whether the levels of expression of 17 candidate genes were associated with locoregional control after breast-conserving treatments of early-stage breast cancers in young, premenopausal women. Methods: Gene expression was measured by using RT-PCR in the breast tumors of a series of 53 young (younger than 40 years), premenopausal patients. All treatments consisted of primary breast-conserving surgery followed by whole-breast radiotherapy (± regional lymph nodes) with or without systemic treatments (chemotherapy ± hormone therapy). The median follow-up was 10 years. Results: The 10-year locoregional control rate was 70% (95% CI, 57% to 87%). In univariate analysis, no clinical/pathologic prognostic factors were found to be significantly associated with decreased locoregional control. Expression of three genes was found to be significantly associated with an increased locoregional recurrence rate: low estrogen-receptor β, low aromatase, and high GATA3. Two others were associated with only a trend (P < 0.10): low HER1 and SKP2. In multivariate analysis, only the absence of aromatase was significantly associated with an increased locoregional recurrence rate (P = 0.003; relative risk = 0.49; 95% CI 0.29 to 0.82). Conclusions: Recent data give credit to the fact that breast cancer in young women is a distinct biologic entity driven by special oncogenic pathways. Our results highlight the role of estrogen-signaling pathways (mainly CYP19/aromatase, GATA3, and ER-β) in the risk of locoregional recurrence of breast cancer in young women. Confirmation in larger prospective studies is needed.
- 17 June 2008
- Vol. 13 (2) , 245-51
The use of computed tomography in radiotherapy treatment planning for breast cancer. How does conventional radiotherapy planning compare with virtual?
To compare, in terms of ballistics and dosimetry, a conventional and a virtual simulation in 14 patients without changing the set-up. 14 women with breast cancer were treated with postoperative radiotherapy from October 2003 to November 2004. Whole breast irradiation alone was indicated (50 Gy at International Committee on Radiation Units [ICRU] point in 25 fractions over 5 weeks) with, in some cases, an additional boost of 16 Gy to the tumor bed--that was not taken into account in this study. After CT scan, tangential fields were conventionally simulated using a Mecaserto Phebus-type simulator-CT scan. The planning target volume (PTV) was the clinical target volume (CTV) expanded with an additional margin of 1 cm in all directions but towards the skin. Both the lungs and the heart were delineated as organs at risk. Dosimetries were computed for the two beams arrangements i.e. 2D conventional and 3D virtual. The mean age of 14 women was 51.4 years (range 26-65). Laterality was the left breast for 6 patients and the right for 8. Few differences were noticeable in terms of gantry angles. The 3D medial fields were more medial with a mean of 8 mm (range 0-15). The 3D lateral fields were more posterior with a mean difference of 8 mm (range 0-25). The dosimetry analysis showed that, with regard to conventional simulations, at least 95% of the CTV received in all cases > 95% of the prescribed dose. However, in 8 out of 14 patients (57%), 15% of the PTV received < 95% of the prescribed dose. The ICRU 50 quality criterion that at least 95% of the PTV (PTV(95%)) should receive at least 95% of the prescribed dose was never met with conventional simulation. In the case of virtual simulation, the ballistics of the treatment were designed to meet the ICRU quality criterion and thus the PTV95% was higher here than with the conventional simulation by a mean of 17.6% +/- 9.7%. The percentage of CTV receiving a dose higher than 107% of the prescribed dose was 21.3% +/- 12% with conventional and 24% +/- 11% with virtual simulation. The high incidence of breast cancer, the essential role of radiotherapy in its treatment and the potential ensuing toxicity explain why so many studies are devoted to the improvements brought to the techniques of this treatment. The virtual planning of the treatment, however, comes up against many difficulties. The countering of the CTV is complex and necessitates a combination of clinical examination and imagery. The choice of margins around the CTV has not been standardised and is largely dependent both on the equipment used and the quality control methods.
- 17 June 2008
- Vol. 13 (2) , 245-51
The use of computed tomography in radiotherapy treatment planning for breast cancer. How does conventional radiotherapy planning compare with virtual?
To compare, in terms of ballistics and dosimetry, a conventional and a virtual simulation in 14 patients without changing the set-up. 14 women with breast cancer were treated with postoperative radiotherapy from October 2003 to November 2004. Whole breast irradiation alone was indicated (50 Gy at International Committee on Radiation Units [ICRU] point in 25 fractions over 5 weeks) with, in some cases, an additional boost of 16 Gy to the tumor bed--that was not taken into account in this study. After CT scan, tangential fields were conventionally simulated using a Mecaserto Phebus-type simulator-CT scan. The planning target volume (PTV) was the clinical target volume (CTV) expanded with an additional margin of 1 cm in all directions but towards the skin. Both the lungs and the heart were delineated as organs at risk. Dosimetries were computed for the two beams arrangements i.e. 2D conventional and 3D virtual. The mean age of 14 women was 51.4 years (range 26-65). Laterality was the left breast for 6 patients and the right for 8. Few differences were noticeable in terms of gantry angles. The 3D medial fields were more medial with a mean of 8 mm (range 0-15). The 3D lateral fields were more posterior with a mean difference of 8 mm (range 0-25). The dosimetry analysis showed that, with regard to conventional simulations, at least 95% of the CTV received in all cases > 95% of the prescribed dose. However, in 8 out of 14 patients (57%), 15% of the PTV received < 95% of the prescribed dose. The ICRU 50 quality criterion that at least 95% of the PTV (PTV(95%)) should receive at least 95% of the prescribed dose was never met with conventional simulation. In the case of virtual simulation, the ballistics of the treatment were designed to meet the ICRU quality criterion and thus the PTV95% was higher here than with the conventional simulation by a mean of 17.6% +/- 9.7%. The percentage of CTV receiving a dose higher than 107% of the prescribed dose was 21.3% +/- 12% with conventional and 24% +/- 11% with virtual simulation. The high incidence of breast cancer, the essential role of radiotherapy in its treatment and the potential ensuing toxicity explain why so many studies are devoted to the improvements brought to the techniques of this treatment. The virtual planning of the treatment, however, comes up against many difficulties. The countering of the CTV is complex and necessitates a combination of clinical examination and imagery. The choice of margins around the CTV has not been standardised and is largely dependent both on the equipment used and the quality control methods.
- 29 February 2008
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 86 (2) , 288
Author’s reply to Dr. Baltoyiannis and colleagues’ letter
- 29 February 2008
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 86 (2) , 288
Author’s reply to Dr. Baltoyiannis and colleagues’ letter